FDA Drug Shortage: Cefotaxime Sodium Powder, for Solution (Current)

The FDA has designated Cefotaxime Sodium Powder, for Solution as currently in shortage due to increased demand. This shortage affects the availability of a critical third-generation cephalosporin antibiotic used to treat serious bacterial infections, including meningitis, septicemia, and intra-abdominal infections. Wholesale drug distributors face immediate allocation challenges as hospitals and specialty pharmacies attempt to secure remaining inventory.

Regulatory Context

The FDA Drug Shortage Program operates under the FDA Safety and Innovation Act (FDASIA) of 2012, which requires manufacturers to notify FDA of anticipated discontinuances or supply interruptions that could lead to a shortage. Under 21 USC 356c, manufacturers of medically necessary drugs must provide at least six months' notice of discontinuances or interruptions.

The FDA maintains the Drug Shortages Database to inform healthcare providers, distributors, and patients of current and resolved shortages. A drug is listed as "currently in shortage" when total market supply does not meet projected demand, as determined by FDA evaluation of manufacturer production data and market demand signals.

Shortage Details

Product: Cefotaxime Sodium Powder, for Solution

Reason: Demand increase for the drug

Status: Current (as of database reporting)

Therapeutic Category: Third-generation cephalosporin antibiotic

Cefotaxime is administered intravenously or intramuscularly and requires reconstitution before use. The powder formulation has a limited shelf life post-reconstitution, typically 12-24 hours under refrigeration depending on concentration. This formulation characteristic means inventory cannot be pre-prepared and stockpiled at the point of care, intensifying the impact of supply constraints.

The FDA has not disclosed whether specific manufacturers have discontinued production, experienced manufacturing disruptions, or whether the shortage results solely from demand exceeding available manufacturing capacity. The agency lists demand increase as the primary driver, which typically indicates that existing manufacturers are producing at or near capacity but cannot scale production quickly enough to meet clinical needs.

Impact on Wholesale Distributors and 3PLs

Wholesale drug distributors holding Cefotaxime inventory face immediate operational decisions regarding allocation methodology. During shortages, distributors must balance historical purchasing patterns, patient population needs, and contractual obligations when determining allocation to downstream customers.

Allocation Documentation: Distributors should document allocation decisions to demonstrate fair and transparent distribution practices. State boards of pharmacy and the FDA Office of Criminal Investigations have investigated allegations of shortage profiteering during previous antibiotic shortages. Documentation should include allocation formulas, customer purchase history, and communications regarding allocation limits.

Secondary Market Activity: Drug shortages create conditions for gray market resellers to acquire and resell product at inflated prices. Under the Drug Supply Chain Security Act (DSCSA), all trading partners in the distribution chain must be authorized and licensed. Distributors approached by unfamiliar entities offering Cefotaxime should verify the entity's licensure status with the relevant state board of pharmacy and confirm NABP accreditation where applicable.

Cold Chain Considerations: While Cefotaxime Sodium Powder for reconstitution is typically stored at controlled room temperature (20-25°C), shortage conditions may lead to longer storage durations and increased handling as distributors manage allocation. Third-party logistics providers handling cGMP storage for manufacturers or distributors should verify that extended storage does not approach expiration dates or expose product to temperature excursions during increased distribution activity.

Inventory Verification: Distributors should audit current Cefotaxime inventory against purchase orders and confirm that all units are within expiration and properly documented in their inventory management systems. Shortage conditions increase the risk of counterfeit product entering the supply chain.

What ColdChainCheck Data Shows

Of the 1,275 wholesale drug distributors and 3PLs tracked in the ColdChainCheck directory, 1,234 hold active FDA registration — the baseline requirement for entities handling Cefotaxime and other prescription drugs. The average compliance score of 51/100 reflects a "Fair" tier, indicating that while most entities meet basic registration requirements, fewer maintain the full spectrum of verified compliance signals including NABP accreditation and clean enforcement records.

During drug shortages, entities with lower compliance scores may present elevated supply chain risk. Of the tracked entities, 73 have at least one FDA recall on record. While recalls do not automatically indicate current compliance deficiencies, shortage conditions create incentives for marginal operators to re-enter the market or for gray market actors to exploit supply gaps. Entities in the "Poor" (38 entities) and "Minimal" (9 entities) tiers lack sufficient verified compliance signals and warrant additional due diligence before engaging in shortage-driven transactions.

Only 63 entities in the directory hold NABP accreditation (formerly VAWD). NABP-accredited distributors undergo facility inspections and quality system audits beyond state licensure requirements. During shortage allocations, sourcing from NABP-accredited entities provides an additional verification layer that the distributor maintains documented quality controls and regulatory compliance processes.

Practical Guidance for Compliance Officers

• Verify trading partner status before accepting shortage inventory: Use the ColdChainCheck directory to confirm that any entity offering Cefotaxime holds active state licensure in the jurisdictions where product will be shipped and received. Cross-reference against the FDA's Registered Wholesalers list and state board of pharmacy databases.

• Prioritize NABP-accredited sources: Filter the directory for entities with NABP accreditation when evaluating new suppliers or unfamiliar trading partners approaching you with shortage product. The 63 accredited entities represent 4.9% of tracked distributors but demonstrate third-party verified compliance.

• Document allocation methodology: If your organization is allocating limited Cefotaxime inventory to downstream customers, document the allocation formula and customer eligibility criteria. Retain this documentation alongside standard DSCSA transaction records in case of regulatory inquiry.

• Monitor for counterfeit product signals: Shortage conditions increase counterfeit risk. Verify that all Cefotaxime transactions include proper DSCSA transaction information, transaction history, and transaction statements as required under 21 USC 360eee-1(d).

ColdChainCheck tracks FDA drug shortage listings as part of ongoing enforcement and compliance signal monitoring. For additional guidance on DSCSA compliance during supply disruptions, see the DSCSA Compliance Guide and Wholesale Distributor Licensing Requirements.

Disclaimer: This article provides informational content based on publicly available FDA drug shortage data as of the publication date. It is not legal or regulatory advice. Wholesale drug distributors should consult legal counsel and verify all compliance requirements with relevant regulatory authorities including the FDA and applicable state boards of pharmacy.